2014
DOI: 10.1016/j.joms.2014.06.306
|View full text |Cite
|
Sign up to set email alerts
|

Denosumab Treatment for Aggressive Multiple Recurrent Familial Central Giant Cell Granulomas

Abstract: Background: Aggressive familial giant-cell granulomas of the jaws can be severely deforming. Surgical and nonsurgical treatments may be associated with multiple recurrences. Denosumab, a new generation antiresorptive drug, is an osteoclast inhibitor, which may be particularly useful to manage such potentially disfiguring lesions. Materials and Methods: Two sisters, both with a history of multiple recurrent aggressive central giant-cell granuloma (CGCG)-like lesions in both jaws, were referred for management. A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 7 publications
0
1
0
Order By: Relevance
“…Subcutaneous denosumab is used for the management of recurrent aggressive lesions and may represent a specific treatment with promising potential. [25] AUTHORS' CONTRIBUTIONS All the authors have actively participated in the redaction, the revision of the manuscript, and provided approval for this final revised version.…”
Section: Discussionmentioning
confidence: 99%
“…Subcutaneous denosumab is used for the management of recurrent aggressive lesions and may represent a specific treatment with promising potential. [25] AUTHORS' CONTRIBUTIONS All the authors have actively participated in the redaction, the revision of the manuscript, and provided approval for this final revised version.…”
Section: Discussionmentioning
confidence: 99%